Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Ruxolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 27 Mar 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 18 Oct 2017 Updated analysis results (n=21) assessing safety and efficacy of the combination of afatinib and ruxolitinib in NSCLC patients who had progressed on EGFR-TKIs, were presented at the 18th World Conference on Lung Cancer.